Opmind Medical Completes Over RMB 200 Million Pre-IPO Financing Round

VCBeat has learned that Guangdong OptoMedic Technologies, Inc. recently completed a Pre-IPO financing round exceeding RMB 200 million. The round was led by Beijing Jianxin Private Equity Fund L.P. and Zhuhai Huajin Capital Co., Ltd., with participation from Guoxin Capital and Shanghai Binfu Investment Management Partnership (L.P.). Within the past year, the company has successively attracted investment from Alibaba, Yahui Investment, China Life Pension Fund, and other renowned institutional investors and strategic partners. Hygeia Capital has served as the exclusive financial advisor across multiple rounds. The proceeds from this round will be used to advance the commercialization of several key innovative products, expand the global marketing network and channels, and further strengthen the company’s comprehensive competitive advantages in the endoscopy field.

OptoMedic, established in 2013 and headquartered in Foshan, is a leading global platform-based innovator in the endoscopy industry. Its product portfolio encompasses host systems and scopes for both rigid and flexible endoscopes, as well as ancillary instruments and contrast agents.

Traditional rigid endoscopes have evolved from 2K to 4K resolution, addressing the need for physicians to “see clearly.” However, the assessment of minute lesions and their margins still relies heavily on physician experience. Against the backdrop of the precision medicine industry’s development, the demand for endoscopes has shifted from enabling physicians to “see clearly” to helping them “understand what they see.” Fluorescence navigation technology visualizes tumors, lymph nodes, ureters, and other structures during surgery, effectively equipping surgeons with a “BeiDou Navigation System” to make procedures more precise, thorough, safe, and reliable.

Fluorescence endoscopes, which integrate both white-light and fluorescence imaging capabilities, offer a broad range of indications and do not alter existing user workflows. They have been included in multiple expert consensus statements and clinical guidelines across Europe, the United States, Japan, and China. Fluorescence endoscopy is expected to become an industry standard in the coming years.

The endoscopy sector suffers from severe homogenization. Core components of low-end domestically produced products have long relied on upstream supply chains, resulting in insufficient product competitiveness and vulnerability to supply chain bottlenecks. Since its inception, OptoMedic has been deeply committed to the independent research and development of foundational technologies across the entire value chain. The company has now fully mastered multiple core technologies in the field of high-end multifunctional endoscopes, including minimally invasive vision technology, intelligent imaging platform technology, and endoscope design and manufacturing technology, thereby establishing a comprehensive core technology platform.

In the field of fluorescence imaging, the company possesses first-mover technological advantages and has established a strong technical moat. It launched the NMPA’s first domestically produced high-definition fluorescence endoscopy system in 2018 and the NMPA’s first 4K fluorescence endoscopy system in 2020. The 214KM, currently under development, is poised to become the world’s first endoscopy system featuring dual-fluorescence staining capabilities.

In the field of 3D imaging, the company is one of the few globally that has mastered 3D optical endoscopy technology. It pioneered the launch of the first domestically produced 4K 3D fluorescence endoscope, which made a stunning debut at the 87th China International Medical Equipment Fair (CMEF). The product’s exceptional 3D fluorescence imaging performance received widespread acclaim from industry experts and investors.

Leveraging its accumulated expertise in single-function endoscopy technologies and its independent development of full-stack underlying technologies, OptoMedic launched Stellar in 2022, China’s first all-in-one endoscopy platform integrating fluorescence imaging, 3D visualization, and 4K resolution. This milestone establishes OptoMedic as an innovation benchmark in the endoscopy field, both in China and globally.

The endoscopy market has long been monopolized by foreign giants such as Storz, Olympus, and Stryker, with imported brands firmly controlling over 90% of the domestic market, resulting in an extremely low localization rate for endoscopes in China. OptoMedic, leveraging its fluorescent endoscopy system as a strategic entry point, has become the first to break the monopoly held by imported brands in the high-end endoscopy sector.

2019 marked the first sales year for OptoMedic’s high-definition fluorescence endoscopy system. The company ranked among the top two in market share within the fluorescence endoscopy niche, becoming the first domestic brand to break through in this sector. In 2021 and 2022, it further secured the number one market share position in this niche for two consecutive years. Currently, OptoMedic’s products are used in over 300 Grade A tertiary hospitals in China, including eight of the top ten such hospitals. Internationally, OptoMedic’s products have entered markets in Germany, Italy, Belgium, and other countries, and have gained recognition from the International Society for Fluorescence Guided Surgery (ISFGS), the most authoritative academic organization in the field.

OptoMedic’s fluorescent endoscopy system serves as the “stepping stone” for its entry into the high-end endoscopy market. The company’s Stellar platform, the first domestically developed 4K 3D fluorescent endoscopy system in China, features fully in-house research, development, and manufacturing of all core components, including the image processor, camera head, cold light source, and endoscope itself. It integrates the company’s core technologies and innovative product functionalities. Furthermore, in 2022, OptoMedic successively launched multiple new products, such as electronic nasopharyngolaryngoscopes, electronic cystorenal pelviscopes, and the first domestically produced electronic choledochoscope. These products were warmly received by the market upon launch, highlighting the company’s strong platform effect. This year, the Stellar system is poised for large-scale commercial deployment. This milestone not only underscores OptoMedic’s position as a global leader in technology and commercialization within this sector but also demonstrates the company’s ambition and capability to achieve comprehensive penetration of the high-end endoscopy brand segment and the broader endoscopy market.

From technological leadership and product leadership to market leadership, OptoMedic is steadily solidifying its global leading position in the endoscopy field.

Dr. An Xin, Founder of the CompanyOptoMedic stated that, leveraging its breakthrough in fluorescence endoscopy, it is continuously launching innovative endoscopic products at a pace of biennial updates, with each update maintaining a leading edge. With the continued support of existing shareholders and further assistance from new investors, the company will enter a new phase characterized by the implementation of a platform-based product pipeline, the establishment of a systematic organizational structure, and the expansion into international markets, aiming to build a globally leading, platform-oriented innovative enterprise in the field of endoscopy.

Jianxin Private Equity Investment TeamIt was stated that the overarching trend toward minimally invasive surgery in China will yield significant clinical benefits, with endoscopes, serving as the “eyes” of surgeons, playing a pivotal role in this shift. This investment in OptoMedic by Beijing Jianxin Private Equity Fund L.P. underscores its recognition of OptoMedic’s first-mover advantage in the field of fluorescence endoscopy. The fund also aims to support the company in establishing a comprehensive product portfolio in the endoscopy sector, thereby further advancing the import substitution of domestically produced medical devices. Meanwhile, Beijing Jianxin Private Equity Fund L.P. will leverage the integrated financial service advantages of the China Construction Bank Group to provide synergistic support and empower the company.

Ms. Liu Feihong, Managing Director of Huajin CapitalIt was stated that the domestic endoscopy market exceeds RMB 20 billion, yet the localization rate stands at only 10%. The Chinese government has explicitly indicated that during the 14th Five-Year Plan period, abdominal endoscopes will be prioritized in terms of planned allocation quantities and access standards. As a platform company specializing in both rigid and flexible endoscopes, OptoMedic holds a competitive advantage over its industry peers. Zhuhai Huajin Capital Co., Ltd., the equity investment platform controlled by Huafa Group, a leading state-owned enterprise in Zhuhai, aims to collaborate with OptoMedic to expand its full product line layout within the broader health industry.

Guoxin Capital Investment TeamIt was stated that in the medical device sector, high-end medical endoscopes have consistently been one of the segments with the lowest domestic substitution rates, with over 80% of the market monopolized by imports. As a revolutionary technology in minimally invasive surgical equipment, fluorescence endoscopy represents the strategic high ground in global competition among endoscope manufacturers. By applying world-leading aerospace optical technologies and engineering expertise to the field of medical endoscopy, the OptoMedic team has broken the import monopoly on fluorescence navigation endoscopes after nearly a decade of accumulation. Its products are now widely used in more than 100 Grade IIIA hospitals across China. The company’s newly launched Stellar Endoscopic Imaging Platform integrates 4K, 3D, and fluorescence capabilities into an all-in-one solution, comprehensively meeting the diverse needs of clinical surgeries. OptoMedic’s achievement in independently developing and manufacturing the Stellar platform signifies that Chinese intelligent manufacturing has reached the highest standards in endoscopic technology. Committed to implementing the principle of “financial services supporting the real economy,” Guoxin Capital is dedicated to empowering small, medium, and micro enterprises and will fully support OptoMedic’s development, thereby promoting the advancement of China’s independent innovation in medical technology.

Mr. Zhu Jian, Partner at Binfu CapitalIt is noted that the trend toward minimally invasive surgery is significant, and endoscopy effectively resolves the contradiction between small surgical incisions and inadequate exposure of the surgical field. Clinical demands have evolved from “being able to see” to “seeing clearly and more realistically,” while product iterations have advanced from white-light and fluorescence imaging to “4K+3D” fluorescence imaging, leaving ample room for continuous innovation. OptoMedic possesses exceptional in-house R&D capabilities in underlying hardware and software, enabling agile product iteration that has matched and gradually surpassed established imported brands. We look forward to the company becoming a global leading brand in the endoscopy field in the near future, and we anticipate that its rich, platform-based pipeline will deliver more pride-inducing surprises.

Mr. Yang Zhenjun, Managing Partner at Hylink CapitalWe are honored to have accompanied OptoMedic through four consecutive rounds of financing, witnessing together the historic moments of the company’s growth. As a global leader in functional endoscopy, Dr. An Xin, the founder, has built a rare, multidisciplinary team that has established OptoMedic as an industry brand boasting both profound technological accumulation within its sector and a platform-oriented product layout. We remain bullish on the company’s development. With continued capital support from this round, driven by the continuous launch of leading iterative products including rigid endoscopes, flexible endoscopes, and single-use endoscopes, the extension and expansion of clinical solutions, and the ongoing coverage of its global layout, OptoMedic is poised to become a leading platform enterprise in the field of endoscopy and minimally invasive surgery in China and globally.